Neutralizing antibody A16 for resisting botulinum toxin A as well as related biological material and application thereof
By designing nanobodies A16 that target botulinum toxin type A, the problem of side effects of traditional antiserum therapy has been solved, achieving highly efficient and safe neutralization of botulinum toxin type A, and providing new treatment and diagnostic methods.
Patent Information
- Application Number
- CN202411144720.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-20
AI Technical Summary
Current technologies lack highly effective and safe drugs for treating botulinum toxin type A poisoning. Traditional antiserum therapy has side effects and is difficult to mass-produce. There is an urgent need to develop specific nanobodies to neutralize botulinum toxin type A.
A nanobody A16 targeting botulinum toxin type A was designed, containing specific CDR and FR region sequences, which can bind efficiently to botulinum toxin type A, and form a nanobody-hFc fusion protein by fusing with the Fc fragment of human immunoglobulin, which can be used to prepare ELISA detection kits and therapeutic drugs.
It achieves highly efficient neutralization of botulinum toxin type A, providing a safe and specific treatment method that replaces traditional antiserum therapy. It has the advantages of rapid preparation and simple structure, and is suitable for the prevention and treatment of botulinum toxin type A poisoning.
Smart Images

Figure HDA0005001900430000011 
Figure HDA0005001900430000012 
Figure HDA0005001900430000013
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and specifically relates to an anti-type A botulinum toxin neutralizing antibody A16 and related biomaterials and applications thereof. Background Art
[0002] Botulinum neurotoxin (BoNT) is an exotoxin that is currently known to be the most toxic to humans and is produced by Clostridium botulinum under anaerobic conditions. The seven major serotypes of botulinum toxin (A, B, C, D, E, F, G) have a molecular weight of 150kD and are composed of a 100kD heavy chain (HC) and a 50kD light chain (LC) connected by a disulfide bond. HC is an important site for binding to the toxin, enabling the toxin to bind irreversibly to nerve cells at the neuromuscular junction and is also important for mediating transmembrane translocation. Serotypes A, B, E and F can cause human botulism, which manifests as flaccid muscle paralysis, dizziness and difficulty breathing. Regardless of the serotype causing the poisoning, similar symptoms will occur and death may occur due to respiratory failure or cardiac arrest.
[0003] So far, no small molecule drug has been approved for the treatment of botulism. Antitoxin therapy is currently the only specific method available for the treatment of botulism. Among them, polyclonal IgG horse antitoxin is the most effective treatment. At the same time, human anti-botulinum immunoglobulin obtained from vaccinated donors has been developed for the treatment of infant botulism, but these therapies have side effects such as serum sickness and hypersensitivity reactions, and production is not easy to scale. Compared with traditional antiserum treatment, monoclonal antibodies are an alternative and safe method for the treatment of poisoning. Their advantages are better patient tolerance, safety, and repeatability, and they have good development prospects. Botulism develops quickly, and vaccination after exposure is useless. Neutralizing antibodies are urgently needed for preventive treatment. Therefore, countries around the world have doubled their attention to the research on botulism.
[0004] Camels produce an unconventional heavy-chain-only antibody (HCAbs) that binds to antigens based on its heavy chain variable domain (nanoantibody or VHH antibody). Nanoantibodies have unique advantages, such as smaller molecular weight, better tissue penetration, and simpler expression in bacteria. At the same time, nanoantibodies can be easily transformed into polymers to enhance their functionality or half-life. Currently, various forms of VHH are used to evaluate the treatment of common respiratory diseases. The outstanding advantages of nanoantibodies make them an ideal alternative to traditional antibodies and gradually become an emerging force in the field of therapeutic drugs and clinical diagnosis.
[0005] Botulinum toxin type A is the most serious serotype posing a threat to humans due to its high potency and long duration of action, with a 50% lethal dose of only 0.1-1 ng / kg for humans. Although there is an urgent need for therapeutic drugs for type A botulism, the feasibility of using VHH for this purpose has not been fully explored. Therefore, there is an urgent need in the art to apply nanobody technology to develop efficient and safe anti-botulinum toxin type A neutralizing nanobodies to replace the serum products supplied on the market to meet human needs. Summary of the invention
[0006] The technical problem to be solved by the present invention is to develop a specific nano-antibody that can effectively neutralize botulinum toxin, provide candidate antibodies for the diagnosis and prevention of botulism, and enrich the means of prevention and treatment of botulism.
[0007] In order to solve the above problems, the present invention provides a nanobody targeting botulinum toxin type A or an antigen-binding fragment containing the nanobody.
[0008] The present invention provides a nanobody targeting botulinum toxin type A or an antigen-binding fragment containing the nanobody, wherein the nanobody has three complementary determining clusters CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is shown in SEQ ID No.2, the amino acid sequence of the CDR2 is shown in SEQ ID No.3, and the amino acid sequence of the CDR3 is shown in SEQ ID No.4.
[0009] The above CDRs are sequences defined based on the analysis results of the IMGT system.
[0010] The nanobodies described herein generally include a VHH consisting of four framework regions (FRs) and three complementarity determining regions (CDRs), referred to as FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4, and the antigen-binding fragment comprises at least a portion of the nanobody that is sufficient to confer the fragment the ability to specifically bind to botulinum toxin type A.
[0011] The four framework regions may be FR1, FR2, FR3 and FR4.
[0012] The amino acid sequence of FR1 is SEQ ID No. 5;
[0013] The amino acid sequence of FR2 is SEQ ID No.6;
[0014] The amino acid sequence of FR3 is SEQ ID No.7;
[0015] The amino acid sequence of FR4 is SEQ ID No.8.
[0016] In the Nanobody or antigen-binding fragment described above, the Nanobody may be any of the following:
[0017] A1) a Nanobody with an amino acid sequence as shown in SEQ ID No. 1;
[0018] A2) A nanobody obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No. 1.
[0019] The protein tag refers to a polypeptide or protein that is fused and expressed with the target protein to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a His tag, a Flag tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, the Fc segment of immunoglobulin G, etc.
[0020] In the present invention, the protein tag is the Fc segment of human immunoglobulin G (hFc).
[0021] In the above-mentioned nanobody, the nanobody consists of the complementary determining cluster region and the framework region.
[0022] The term "antibody" in the present invention is a heterotetrameric glycoprotein of about 150,000 daltons with identical structural features, which consists of two identical light chains (L) and two identical heavy chains (H). Each light chain is connected to the heavy chain by a covalent disulfide bond, while the number of disulfide bonds between the heavy chains of different immunoglobulin isotypes varies. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. One end of each heavy chain has a variable region (VH), followed by multiple constant regions. One end of each light chain has a variable region (VL) and the other end has a constant region; the constant region of the light chain is opposite to the first constant region of the heavy chain, and the variable region of the light chain is opposite to the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.
[0023] In the present invention, the terms "single domain antibody (VHH)" and "nanobody" have the same meaning and refer to
[0024] The variable region of the antibody heavy chain is cloned to construct a single-domain antibody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with complete functions. Usually, antibodies that naturally lack light chains and heavy chain constant regions 1 (CH1) are first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody (VHH) consisting of only one heavy chain variable region.
[0025] The above-mentioned antigen-binding fragment may be a complete antibody, a fusion antibody, an antibody-drug conjugate, a Fab fragment, a Fv fragment, a Fab' fragment, a F(ab')2 fragment, a single-chain antibody (ScFv), or a minimum recognition unit (MRU) containing the nanobody.
[0026] The term "Fab fragment" is a heterodimer formed by the heavy chain Fd and the complete light chain bound by a disulfide bond, and contains only one antigen binding site. The above-mentioned heavy chain Fd refers to about 1 / 2 of the H chain portion in Fab (containing about 225 amino acid residues, including VH, CH1 and part of the hinge region).
[0027] The term "Fv fragment" refers to the construction of vectors containing VH and VL genes respectively, co-transfection of cells, expression of them separately, and then assembly into functional Fv antibodies; or a stop codon can be set between VH and VL in the vector to express two small molecule protein fragments separately, and then form Fv antibodies (Fv fragments) through non-covalent bonds.
[0028] The term "Fab' fragment" contains one light chain and a portion of one heavy chain including the VH domain and the CH1 domain and the region between the CH1 and CH2 domains, whereby an interchain disulfide bond can be formed between the two heavy chains of the two Fab' fragments to form a F(ab')2 molecule.
[0029] The term "F(ab')2 fragment" contains two light chains and two heavy chains comprising a portion of the constant region between the CH1 and CH2 domains, whereby an interchain disulfide bond is formed between the two heavy chains. Thus, the F(ab')2 fragment consists of two Fab' fragments held together by a disulfide bond between the two heavy chains.
[0030] The term "variable" in the present invention means that some parts of the variable region in the antibody are different in sequence, which forms the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the variable region of the antibody. It is concentrated in three segments called complementary determining regions (CDRs) or hypervariable regions in the variable regions of the light chain and heavy chain. The more conservative part of the variable region is called the framework region (FR). The variable region of the natural heavy chain and light chain each contains four FR regions, which are roughly in a β-folded configuration, connected by three CDRs forming a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and together with the CDRs of the other chain form the antigen binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Volume I, 647-669 pages (1991)). The constant region does not directly participate in the binding of the antibody to the antigen, but they exhibit different effector functions, such as participating in the antibody-dependent cytotoxicity of the antibody.
[0031] In some embodiments, the Nanobodies described herein may be truncated at the N- or C-terminus so that they comprise only part of FR1 and / or FR4, or lack one or both of those framework regions, as long as they substantially retain antigen binding and specificity.
[0032] In the present invention, the nanobody is named nanobody A16.
[0033] The present invention also provides a biomaterial related to the nanobody described above, and the biomaterial may be any of the following:
[0034] B1) a nucleic acid molecule encoding a Nanobody or antigen-binding fragment as described above;
[0035] B2) an expression cassette containing the nucleic acid molecule described in B1);
[0036] B3) a recombinant vector containing the nucleic acid molecule described in B1);
[0037] B4) a recombinant vector containing the expression cassette described in B2);
[0038] B5) a recombinant microorganism containing the nucleic acid molecule described in B1);
[0039] B6) a recombinant microorganism containing the expression cassette described in B2);
[0040] B7) a recombinant microorganism containing the recombinant vector described in B3);
[0041] B8) A recombinant microorganism containing the recombinant vector described in B4).
[0042] In the above biological materials, the nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as mRNA or hnRNA.
[0043] In the above-mentioned biological material, the expression cassette described in B2) refers to a DNA capable of expressing the nanobody in a host cell, which may include not only a promoter for initiating transcription of the nanobody encoding gene, but also a terminator for terminating transcription of the nanobody encoding gene. Further, the expression cassette may also include an enhancer sequence.
[0044] Existing expression vectors can be used to construct a recombinant vector containing the expression cassette.
[0045] In the above biological materials, the vector may be a plasmid, a cosmid, a phage or a virus vector.
[0046] In the above-mentioned biological material, the recombinant vector may be a recombinant vector obtained by introducing the nucleic acid molecule described in B1) into the nanobody-hFc fusion protein expression vector pTSE-hFc.
[0047] In the above biological materials, the microorganisms may be bacteria (such as Escherichia coli), yeast, algae or fungi.
[0048] In the above-mentioned biological material, the nucleic acid molecule B1) may be a nucleic acid molecule encoding the nanobody described above, in which the CDR1 encoding gene is nucleotides 76-99 of SEQ ID No.9, the CDR2 encoding gene is nucleotides 151-174 of SEQ ID No.9, and the CDR3 encoding gene is nucleotides 289-336 of SEQ ID No.9.
[0049] In the above biological material, the nucleic acid molecule in B1) can be any of the following:
[0050] C1) a DNA molecule whose nucleotide sequence is shown as SEQ ID No.9;
[0051] C2) a DNA molecule that hybridizes under stringent conditions with the DNA molecule defined in C1) and encodes said Nanobody;
[0052] C3) A DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85% or more than 80% homology with the DNA sequence defined in C1) or C2) and encodes the Nanobody.
[0053] Wherein, the stringent conditions may be as follows: 50°C, hybridization in a mixed solution of 7% sodium dodecyl sulfate (SDS), 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 2×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 1×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 0.5×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 0.1×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 0.1×SSC, 0.1% SDS; Hybridize in a mixed solution of SDS, 0.5M Na3PO4 and 1mM EDTA, and rinse in 0.1×SSC, 0.1% SDS at 65°C. Alternatively, hybridize in a solution of 6×SSC, 0.5% SDS at 65°C, and then wash the membrane once with 2×SSC, 0.1% SDS and once with 1×SSC, 0.1% SDS.
[0054] A person skilled in the art can easily mutate the nucleotide sequence of the gene encoding the Nanobody A16 described in B1) of the present invention by using known methods, such as directed evolution and point mutation. Those artificially modified nucleotides having 75% or more identity with the nucleotide sequence of A16 described in B1) of the present invention, as long as they encode the Nanobody and have the activity of Nanobody A16, are derived from the nucleotide sequence of the present invention and are equivalent to the sequence of the present invention.
[0055] The present invention also provides a method for preparing the above-mentioned nanoantibody, which may include the following steps: introducing a nucleic acid molecule encoding the nanoantibody described above into a recipient cell to obtain a transgenic cell expressing the nanoantibody, and culturing the transgenic cell to obtain the nanoantibody.
[0056] Furthermore, the nucleic acid molecule encoding the nanobody is the nucleic acid molecule described above.
[0057] In the above method, the nucleotide sequence of the nucleic acid molecule encoding the Nanobody described above can be any of the following:
[0058] C1) a DNA molecule whose nucleotide sequence is shown as SEQ ID No.9;
[0059] C2) a DNA molecule that hybridizes under stringent conditions with the DNA molecule defined in C1) and encodes said Nanobody;
[0060] C3) A DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85% or more homology with any of the DNA sequences defined in C1) to C2) and encodes the Nanobody.
[0061] The full-length nucleotide sequence of the antibody of the present invention or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis. For example, the relevant sequence is synthesized by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by first synthesizing multiple small fragments and then connecting them.
[0062] Furthermore, the receptor cells may be prokaryotic cells, such as bacterial cells; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Specifically, they may be: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells such as CHO, COS7, 293 cells, etc.
[0063] In a specific embodiment of the present invention, the receptor cell can be FreeStyle TM HEK293-F cells.
[0064] The present invention also provides a nanobody-hFc fusion protein, wherein the nanobody-hFc fusion protein is a fusion of the nanobody or antigen binding fragment described above with another molecule, wherein the other molecule may include the Fc domain of an immunoglobulin, a fluorescent protein, or a VHH with different specificities.
[0065] In a specific embodiment of the present invention, the other molecule is the Fc domain of a human immunoglobulin.
[0066] In a specific embodiment of the present invention, the amino acid sequence of the Fc domain of the human immunoglobulin described above is positions 126-352 of SEQ ID No.11.
[0067] In a specific embodiment of the present invention, the Nanobody-hFc fusion protein described above may be any of the following:
[0068] N1) a fusion protein with an amino acid sequence as shown in SEQ ID No.11;
[0069] N2) A protein obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No.11.
[0070] In the above-mentioned Nanobody-hFc fusion protein, the nucleic acid molecule encoding the fusion protein may be any of the following:
[0071] D1) a DNA molecule whose nucleotide sequence is shown as SEQ ID No.10;
[0072] D2) a DNA molecule that hybridizes with the DNA molecule defined in D1) under stringent conditions and encodes the fusion protein;
[0073] D3) A DNA molecule that has 99% or more, 95% or more, 90% or more, 85% or more, or 80% or more homology with the DNA sequence defined in D1) or D2) and encodes the fusion protein.
[0074] The present invention also provides an ELISA detection kit targeting botulinum toxin type A, wherein the kit comprises the nanoantibody, the biomaterial or the fusion protein described above.
[0075] The present invention also provides any of the following applications:
[0076] E1) Use of the aforementioned Nanobody or antigen-binding fragment in the preparation of a product for detecting botulinum toxin type A;
[0077] E2) Use of the aforementioned biological material in the preparation of a product for detecting botulinum toxin type A;
[0078] E3) Application of the above-mentioned preparation method in the preparation of a product for detecting botulinum toxin type A;
[0079] E4) Use of the above-mentioned kit in the preparation of a product for detecting botulinum toxin type A;
[0080] E5) Use of the aforementioned Nanobody in the preparation of a product bound to botulinum toxin type A;
[0081] E6) Use of any of the above-mentioned biological materials in the preparation of a product combined with botulinum toxin type A;
[0082] E7) Use of the above-mentioned preparation method in the preparation of a product combined with botulinum toxin type A;
[0083] E8) Use of the kit described above in the preparation of a product combined with botulinum toxin type A;
[0084] E9) Use of the aforementioned nanoantibody or antigen-binding fragment in the preparation of a botulinum toxin type A detection reagent;
[0085] E10) Use of the aforementioned nanoantibodies or antigen-binding fragments in the preparation of a botulinum toxin type A diagnostic reagent;
[0086] E11) Use of the nanoantibodies or antigen-binding fragments described above in the preparation of drugs for the prevention and / or treatment of botulinum toxin type A.
[0087] The above-mentioned product may be a medicine.
[0088] The present invention includes not only complete antibodies, but also fragments of the nanobodies or fusion proteins formed by antibodies and other sequences with immunological activity. Therefore, the present invention also includes polypeptides such as fragments, derivatives and analogs of the nanobodies that retain the same biological functions or activities as the antibodies of the present invention. The polypeptides may be as follows: D1) a single-chain antibody containing the nanobodies described above; D2) a Fab containing the nanobodies described above; D3) a complete antibody containing the nanobodies described above; D4) a fusion antibody containing the nanobodies described above; D5) an antibody-drug conjugate containing the nanobodies described above.
[0089] D4) The fusion antibody of the nanobody may be: N1) a nanobody-hFc fusion protein having an amino acid sequence as shown in SEQ ID No.11.
[0090] As known to those skilled in the art, the conjugates and fusion antibody expression products include: drugs, toxins, cytokines (cytokines), radionuclides, enzymes and other diagnostic or therapeutic molecules combined with the antibodies of the present invention or their fragments to form conjugates. The present invention also includes cell surface markers or antigens combined with the nano antibodies or their fragments.
[0091] The present invention includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) having a heavy chain containing a variable region, as long as the variable region is identical to or at least 90% homologous to the heavy chain variable region of the antibody of the present invention, preferably at least 95% homologous.
[0092] The present invention prepares a phage nanoantibody display library by immunizing camels with antigens and screens to obtain nanoantibody molecules capable of neutralizing botulinum toxin type A. Nanoantibodies have the advantages of rapid preparation, simple structure and easy transformation into multi-specific antibodies. They are expected to be developed into highly efficient and safe anti-botulinum toxin type A neutralizing nanoantibodies to replace serum products supplied on the market to meet human needs. BRIEF DESCRIPTION OF THE DRAWINGS
[0093] Figure 1 This is the binding status of some phage clones with target antigen or control antigen after the third round of screening by Phage-ELISA. The odd-numbered columns are target antigens, and the even-numbered columns are control antigens.
[0094] Figure 2 The SDS-PAGE electrophoresis is used to detect the purified anti-botulinum toxin type A nanobody-hFc fusion protein A16-hFc. M is a marker band, lane 1 is the non-reducing SDS-PAGE detection result of A16-hFc, and lane 2 is the reducing SDS-PAGE detection result of A16-hFc.
[0095] Figure 3 This is a test for the binding activity of anti-botulinum toxin type A nanobody-hFc fusion protein A16-hFc.
[0096] Figure 4 It is a specific detection of anti-type A botulinum toxin nanobody-hFc fusion protein A16-hFc. AHc, BHc, EHc, and FHc are the Hc antigens of the four serotypes of botulinum toxin A, B, E, and F, respectively; THc is the Hc antigen of tetanus toxin; and AL-HN is the L-HN antigen of type A botulinum toxin.
[0097] Figure 5 The neutralization activity of anti-botulinum toxin type A nanobody-hFc fusion protein A16-hFc was evaluated. BoNT / A is botulinum toxin type A, Ab is the Fc fusion protein A16-hFc of anti-botulinum toxin type A nanobody A16 and human immunoglobulin, and BAT-A is a standard solution of botulinum antitoxin type A from horse. DETAILED DESCRIPTION
[0098] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0099] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0100] Unless otherwise specified, the quantitative tests in the following examples were performed three times and the results were averaged.
[0101] The botulinum toxin type A (BoNT / A) and the equine botulinum antitoxin standard solution (BAT-A) in the following examples were purchased from the China Food and Drug Inspection Institutes.
[0102] The pTSE-hFc in the following examples is obtained by connecting the gene of the Fc domain of human immunoglobulin to the pCMV vector. pTSE-hFc has been recorded in: Xie Qing, Li Zhiying, Zhang Wei, et al. Screening and identification of antibodies against the protective antigen V of plague bacteria [J]. Chinese Journal of Pathogenic Biology, 2022, 17(03): 266-271. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiment of the present invention and cannot be used for other purposes.
[0103] The NEN-SCFV in the following examples is obtained by connecting the genes of the bacteriophage surface protein pill and the arabinose operon to the pET vector. NEN-SCFV has been recorded in: Chen L, Lu J, Yue J, Wang R, Du P, Yu Y, Guo J, Wang X, Jiang Y, Cheng K, Yang Z, Zheng TA humanized antihuman adenovirus 55 monoclonal antibody with good neutralization ability. Front. Immunol. 2023; 14: 1132822. doi: 10.3389 / fimmu.2023.1132822. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiment of the present invention and cannot be used for other purposes.
[0104] The Hc antigens of the four serotypes A, B, E, and F of botulinum toxin, BoNT / A-Hc, BoNT / B-Hc, BoNT / E-Hc, and BoNT / F-Hc in the following examples are prepared by this laboratory, and the preparation method has been recorded in: Shi DY, Liu FJ, Li ZY, Mao YY, Lu JS, Wang R, Pang XB, Yu YZ, Yang ZX. Development and evaluation of atetravalent botulinum vaccine. Hum Vaccin Immunother. 2022; 18(5): 2048621. doi: 10.1080 / 21645515.2022.2048621. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0105] The Hc antigen of tetanus toxin in the following examples was prepared by this laboratory, and the preparation method has been recorded in: Liu XY, Wei DK, Li ZY, Lu JS, Xie XM, Yu YZ, Pang XB. Immunogenicity and immunoprotection of the functional TL-HN fragment derived from tetanustoxin. Vaccine. 2023 Oct 8: S0264-410X(23)01102-7. doi: 10.1016 / j.vaccine.2023.09.032. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0106] The L-HN antigen of botulinum toxin type A in the following examples was prepared by our laboratory, and the preparation method has been described in: Liu FJ, Shi DY, Mao YY, Xiong XH, Lu JS, Pang XB, Dong XJ, Yang ZX, Yu YZ. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A. Vaccine. 2020; 38(14): 2978-2983. doi: 10.1016 / j.vaccine.2020.02.060. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0107] The unrelated control antibody (T23) in the following examples was prepared by this laboratory. The preparation method is as follows: immunizing camels with tetanus TL-HN protein, isolating camel peripheral blood lymphocytes, amplifying VHH gene fragments by nested PCR, constructing a specific nanobody phage library and screening to obtain nanobody molecules that specifically bind to TL-HN protein, and one of the antibodies is named T23. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiment of the present invention and cannot be used for other purposes.
[0108] The following examples used GraphPad Prism 8 statistical software to process the data, and the experimental results were expressed as mean ± standard deviation. One-way ANOVA test was used, and P < 0.05 (*) indicated a significant difference, P < 0.01 (**) indicated a very significant difference, and P < 0.001 (***) indicated a very significant difference.
[0109] Example 1. Construction of anti-botulinum toxin type F nanobody library
[0110] 1. Camel Immunity
[0111] The BoNT / A-Hc antigen was mixed with an equal volume of Freund's complete adjuvant (Sigma, F5881), shaken and emulsified, and after sufficient emulsification, injected into healthy adult Bactrian camels by subcutaneous multi-point injection. Thereafter, booster immunizations were performed every two weeks. Except for the first immunization using Freund's complete adjuvant, all other immunizations used Freund's incomplete adjuvant (Sigma, F5506).
[0112] 2. Isolation of peripheral blood lymphocytes from camels
[0113] 150 mL of peripheral blood from camels that had been immunized five times was collected into anticoagulation tubes to separate peripheral blood lymphocytes (PBMC). The whole blood sample was gently diluted and mixed with lymphocyte separation solution (STEMCELL, 07851) to form a mixture with a clear interface between the two to separate peripheral blood lymphocytes from camel blood. After the mixture of whole blood and lymphocyte separation solution was centrifuged, the liquid in the centrifuge tube was divided into four layers from top to bottom: plasma layer, PBMC layer, lymphocyte separation solution layer and red blood cell layer.
[0114] 3. Nested PCR amplification of VHH gene fragments
[0115] Total RNA from PBMCs was extracted using the OMEGA EZNA Total RNA kit I (OMEGA, R6834), and then reverse transcribed using the Invitrogen SuperscriptⅢ First-strand synthesis system for RT-PCR kit (Invitrogen, 18080-051) to obtain cDNA.
[0116] The first round of PCR: using the synthesized cDNA as a template, the antibody CH2 region sequence was PCR amplified with the designed IgG-specific upstream primer CALL001 and downstream primer CALLOO2; using the recovered first-round PCR product as a template, the second round of PCR amplification was performed with the designed primers VHH-F and VHH-R to amplify the VHH fragment.
[0117] Table 1. Primer sequences used in two rounds of PCR
[0118] Primer name Primer sequence (5'-3') CALL001 GTCCTGGCTGCTCTTCTACAAGG CALL002 GGTACGTGCTGTTGAACTGTTCC VHH-F cggCCATGGcGGTCCTGGCTGCTCTTCTACA VHH-R tcccGCGGCCGCTGAGGAGAYGGTGACCWGGGT
[0119] 4. Electroporation products
[0120] The vector NEN-SCFV and the amplified VHH gene were digested with restriction endonucleases NcoⅠ and NotⅠ, and the ligation products were constructed by ligation with T4 ligase.
[0121] The ligation product was transformed into E. coli TG1 competent cells (Beijing Huayueyang Biotechnology Co., Ltd., WG1220) using electroporation technology to construct an anti-F type botulinum toxin specific phage antibody library. The phage antibody library was diluted in multiples to determine its capacity and transformation efficiency. It was identified that the library capacity of this antibody library reached 4×10 8 To detect the accuracy of the library, 48 clones were randomly selected for colony PCR, and sequence comparison results showed that the VHH fragment insertion rate reached 100% and the sequences were different.
[0122] Example 2: Screening of anti-botulinum toxin type A specific nanobody phage library
[0123] BoNT / A-Hc was used as an antigen and the constructed nanobody phage library was used for solid phase screening to obtain anti-botulinum toxin type A specific nanobody.
[0124] Prepare the following solution:
[0125] 2YT-GA medium (1 L): 16 g Typtone, 10 g Yeast Extract, 5 g NaCl, 100 μg / mL ampicillin, 20% glucose, and the rest water.
[0126] 2YT-KAA medium (1 L): 16 g Typtone, 10 g Yeast Extract, 5 g NaCl, 100 μg / mL kanamycin, 20% glucose, final concentration 1 mM arabinose, and the rest water.
[0127] 20% PEG / NaCl solution (1 L): 200 g PEG6000, 146.25 g NaCl, and the rest water.
[0128] PBST solution (1 L): 8.0 g NaCl, 0.2 g KCl, 1.42 g Na2HPO4, 0.27 g KH2PO4, 0.1% Tween-20, and the rest water.
[0129] Take the constructed anti-type A botulinum toxin specific nanoantibody phage library bacterial solution and transfer it to 2YT-GA medium and culture it to the logarithmic growth phase. Add M13KO7 helper phage (NEW ENGLAND BioLabs, N0315S) at a ratio of MOI≈10, let it stand for infection at room temperature for 30 minutes, and then culture it at 37°C and low speed 150rpm for 30 minutes; place the deep-well plate at a speed of 4000rpm, centrifuge it at room temperature for 15 minutes, discard the supernatant, and use 2YT-KAA medium for overnight display. Collect the culture display supernatant on the second day, concentrate the phage with 20% PEG / NaCl solution, and obtain the high-titer antibody library display product for subsequent screening. Use the nanobody phage library to screen specific nanoantibodies on a solid phase. Coat the BoNT / A-Hc protein with 0.05M NaHCO3 coating solution (pH=9.6) to the immunotube and incubate overnight at 4°C. The next day, wash the immunotube twice with PBS for 3 minutes each time. Block it with a blocking solution (2% bovine serum albumin) at room temperature for 2 hours, then add the nanobody phage library solution and incubate it at room temperature for 2 hours; shake it at a low speed of 200 rpm for 20 minutes; wash it with PBST 10 times, and then wash it with PBS 5 times. After washing, add 1mL of elution solution (0.1M Glycine-HCl, pH 2.2) and elute it at 400rpm for 20 minutes under the shaking condition; take out the elution solution in the target antigen immunotube, add 20-60μL of neutralization solution (1M Tris-HCl, pH 8.0) for neutralization; Escherichia coli TG1 in the logarithmic growth phase was infected, and after standing at room temperature for 30 minutes, it was cultured at 37°C and 150 rpm for 30 minutes to produce and purify phages for the next round of screening. The same screening process was repeated for 3 rounds, and the enrichment results are shown in Table 2.
[0130] Table 2. Analysis of the enrichment degree of anti-botulinum toxin phage nanoantibody library screening
[0131] Screening times Input amount (pfu) Output (pfu) Output / Input 1 <![CDATA[5.0×10 11 ]]> <![CDATA[9.0×10 5 ]]> <![CDATA[1.8×10 -6 ]]> 2 <![CDATA[1.2×10 11 ]]> <![CDATA[5.0×10 6 ]]> <![CDATA[4.2×10 -5 ]]> 3 <![CDATA[1.2×10 11 ]]> <![CDATA[6.6×10 8 ]]> <![CDATA[5.5×10 -3 ]]>
[0132] After the above three rounds of screening, single clones with obvious intervals and regular shapes were selected from the plates with good phage growth, and inoculated into 96-well deep-well plates containing 250 μL of 2YT-GA medium in each well, of which 2 clones not inoculated or inoculated with other antibodies were left as negative control wells; after the bacterial solution was cultured at 37°C to the logarithmic growth phase, M13KO7 helper phage was added at a ratio of MOI≈10, that is, 100 μL was added to each well of the deep-well plate where a single phage clone was cultured, and the infection was allowed to stand at room temperature for 30 minutes, and then cultured at 37°C and a low speed of 150 rpm for 30 minutes; the deep-well plate was placed at a speed of 2000 rpm, centrifuged at room temperature for 10 minutes, and then the supernatant was discarded, and expression was induced using arabinose containing a final concentration of 1 mM, and cultured overnight at 28°C and a speed of 220 rpm to obtain phage particles displaying nanoantibodies.
[0133] Example 3: Identification of botulinum toxin type A specific nanobodies using phage-ELISA
[0134] The BoNT / A-Hc protein was used as the antigen to coat the ELISA plate, and the antigen concentration was diluted to 2 ng / μL with 0.05M NaHCO3 coating solution, with a dosage of about 200 ng / well. The adjacent columns of the antigen column were coated with 2% BSA antigen in parallel as a negative control, and coated at 4°C overnight; the ELISA plate was taken out the next day, washed 6 times with PBST on a plate washer, and then blocked with blocking solution (30g skim milk powder added to 1L PBS) at 200μL / well, and blocked at 37°C for 2h; the monoclonal bacterial solution induced overnight was centrifuged at 4°C and 3000rpm for 10min, and 125μL supernatant of each bacterial solution was taken into a 96-well deep-well plate with 125μL blocking solution, and pre-bound for 30min; the blocked induced expression supernatant was added to the corresponding ELISA plate coated with the target antigen and the control antigen at 100μL / well, and incubated at 37°C for 1.5h.
[0135] After washing with PBST on a plate washer for 6 times, HRP-labeled anti-M13 mouse monoclonal antibody (Sino Bioligical, 1973-MM05T-H) was diluted 4000 times with blocking solution, added to the ELISA plate at 100 μL / well, and incubated at 37°C for 45 min; washed with PBST on a plate washer for 6 times, prepared color development solution (10 mL of color development solution containing 1 mL 10×OPD, 9 mL of a mixed solution of 0.2 M Na2HPO4 and 0.1 M citric acid, and 10 μL of 30% hydrogen peroxide), added to the ELISA plate at 100 μL / well, and color was developed for 15-20 minutes in the dark; 2 M H2SO4 stop solution was added, 50 μL / well to terminate the reaction; using an ELISA reader, readings were taken at dual wavelengths of 492 / 630 nm, and monoclones with a light absorption value ratio of the antigen group to the negative control group greater than 5 were determined as positive clones. Some Phage-ELISA experimental results are shown in Figure 1 The odd-numbered columns are target antigens, and the even-numbered columns are control antigens. The bacterial solution corresponding to the positive clones was sent to a biotechnology service company for sequence determination to obtain the DNA sequence of the inserted fragment, and finally a sequence of a phage clone A16 that can specifically bind to BoNT / B-Hc was obtained.
[0136] The amino acid sequence of A16 is shown in SEQ ID No.1: it includes a framework region (FR: FR1, FR2, FR3, FR4) and a complementary determining region (CDR: CDR1, CDR2, CDR3), the four parts of the framework region are sequentially recorded as SEQ ID No.5, SEQ ID No.6, SEQ ID No.7, and SEQ ID No.8; the three parts of the complementary determining region are sequentially recorded as SEQ ID No.2, SEQ ID No.3, and SEQ ID No.4.
[0137] Wherein SEQ ID No.1:
[0138] QVPLVESGGGSVQAGGSLRLSCAASGDTYGSYCMGWFRQAPGKERERVAMIWPGTGHTYNADSVKGRFTV SHDKAKNTLYLQMNSLKPEDTAMYYCAATFAGECASWDGMDYWGKGTQVTVSS;
[0139] SEQ ID No. 2: GDTYGSYC;
[0140] SEQ ID No. 3: IWPGTGHT;
[0141] SEQ ID No.4:AATFAGECASWDGMDY;
[0142] SEQ ID No.5: QVPLVESGGGSVQAGGSLRLSCAAS;
[0143] SEQ ID No.6: MGWFRQAPGKERERVAM;
[0144] SEQ ID No.7: YNADSVKGRFTVSHDKAKNTLYLQMNSLKPEDTAMYYC;
[0145] SEQ ID No. 8: WGKGTQVTVSS.
[0146] The nucleotide sequence of the gene encoding the above-mentioned anti-botulinum toxin type A nanobody A16 is shown in SEQ ID No.9.
[0147] SEQ ID No.9:
[0148] CAGGTGCCGCTGGTGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGAGACACCTACGGTAGCTACTGCATGGGCTGGTTCCGCCAGGCTCCAGGGAAGGAGCGCGAGCGGGTCGCAATGATTTGGCCTGGTACTGGTCACACATACAATGCCGA CTCCGTGAAGGGCCGATTCACCGTCTCCCATGACAAAGCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAAACCTGAGGACACTGCCATGTACTACTGTGCGGCAACCTTCGCGGGGGAGTGCGCGTCGTGGGATGGCATGGACTACTGGGGCAAAGGAACCCAGGTCACCGTCTCCTCA.
[0149] Example 4. Preparation of anti-botulinum toxin type A nanobody-hFc fusion protein
[0150] 1. Construction of anti-botulinum toxin type A nanobody-hFc fusion protein eukaryotic expression plasmid pTSE-A16-hFc
[0151] According to the anti-botulinum toxin type A nanobody gene sequence (SEQ ID No.9), its carboxyl terminus was connected to the hFc segment of human immunoglobulin to form an anti-botulinum toxin type A nanobody-hFc fusion protein. The encoding nucleotide sequence of this fusion protein is shown in SEQ ID No.10, and the amino acid sequence of the fusion protein is shown in SEQ ID No.11.
[0152] SEQ ID No.10:
[0153]
[0154] SEQ ID No.11:
[0155] QVPLVESGGGSVQAGGSLRLSCAASGDTYGSYCMGWFRQAPGKERERVAMIWPGTGHTYNADSVKGRFTVSHDKAKNTLYLQMNSLKPEDTAMYYCAATFAGECASWDGMDYWGKGTQVTVSSASDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK.
[0156] The obtained A16 gene sequence was cloned into the pTSE-hFc expression vector through basic PCR amplification, restriction digestion, ligation and other techniques, and a single clone was selected for sequencing verification. After the amplified VHH gene fragment was successfully inserted into the corresponding vector, a eukaryotic expression plasmid was constructed, and the obtained recombinant plasmid was named pTSE-A16-hFc.
[0157] The structure of the recombinant vector pTSE-A16-hFc is described as follows: a DNA fragment having a sequence of SEQ ID No. 9 is inserted between the recognition sites of restriction endonucleases Sal I and Nhe I of the pTSE-hFc vector, and the other sequences of the pTSE-hFc vector are kept unchanged to obtain a recombinant vector.
[0158] 2. Expression and purification of anti-botulinum toxin nanobody-hFc fusion protein
[0159] The constructed pTSE-A16-hFc expression plasmid was transfected into FreeStyle TM In HEK293-F cells (Invitrogen, R79007), cell activity was monitored daily starting after 72 hours. When the cell activity dropped from 95-100% to 80-85%, the cell supernatant was collected for purification to obtain the nanobody-hFc fusion protein A16-hFc.
[0160] The purified antibody was analyzed by SDS-PAGE electrophoresis. Figure 2 As shown: The molecular weight of the antibody is in line with expectations, and the band size of the nanobody-hFc fusion protein under reducing conditions is approximately 40 kDa ( Figure 2 Lane 2), the band size under non-reducing conditions is approximately 80 kDa ( Figure 2 middle lane 1).
[0161] Example 5. Evaluation of properties of nanobody-hFc fusion protein
[0162] The binding activity between the nanobody-hFc fusion protein A16-hFc and the BoNT / A-Hc protein was detected by ELISA experiment. The experimental method is as follows:
[0163] The BoNT / A-Hc protein concentration was diluted to 2 μg / mL with carbonate coating buffer (pH 9.6), and 100 μL / well was added to a 96-well ELISA plate for coating overnight at 4°C. The coating solution was discarded and the plate was washed with PBST (1 L PBS solution containing 8.0 g NaCl, 0.2 g KCl, 1.42 g Na2HPO4, 0.27 g KH2PO4, 0.1% Tween-20) for 6 times, pat dry the residual liquid in the plate, add blocking solution (3% skim milk powder) at 200 μL / well, and block at 37°C for 2 h; dilute the antibody for binding activity detection by 2 times with blocking solution, with an initial dilution of 50 μg / mL, discard the blocking solution in the plate, wash 6 times with PBST, pat dry the residual liquid, add A16-hFc to be tested at 100 μL / well to the plate, and incubate at 37°C for 1.5 h; dilute with blocking solution at 1:4000 Dilute HRP-labeled goat anti-human IgG in proportion, discard the primary antibody, wash 6 times with PBST, add 100 μL / well to the plate, and incubate at 37°C for 45 minutes; discard the secondary antibody, wash 6 times with PBST, add 100 μL / well peroxidase substrate colorimetric solution, color for 15-20 minutes in the dark, observe the color development effect, add 50 μL / well 2M sulfuric acid to terminate the reaction after color development is complete; use a microplate reader at 492nm / 630nm dual wavelength to measure the optical density value. By calculating the concentration required for the antibody to bind 50% of the antigen protein (EC 50 ), and evaluate the binding ability between them.
[0164] The results are as follows Figure 3 As shown, the analysis showed that the half effective concentration (EC 50 ) is 11.86nM.
[0165] The specificity of the nanobody-hFc fusion protein was identified by ELISA experiment. The experimental method is as follows:
[0166] BoNT / A-Hc, BoNT / B-Hc, BoNT / E-Hc, BoNT / F-Hc, BoNT / AL-HN, and TeNT-Hc were diluted to 2 μg / mL with carbonate coating buffer, and 100 μL / well was added to a 96-well ELISA plate and coated overnight at 4°C. The next day, the coating solution was discarded, and the 96-well plate coated overnight was washed 6 times with PBST (0.1% Tween-20) on a plate washer. The residual liquid in the wells was patted dry, and blocking solution (3% skim milk powder) was added at 200 μL / well, and the plate was blocked at 37°C for 2 h. A16-hFc protein primary antibody solution was prepared, the antibody concentration was diluted to 2 μg / mL, the blocking solution was discarded, and P After washing with BST for 6 times, pat dry, add A16-hFc at 100 μL / well, and incubate at 37°C for 1.5 h; dilute HRP-labeled goat anti-human IgG with blocking solution at a ratio of 1:4000, discard the primary antibody, wash 6 times with PBST, add to the plate at 100 μL / well, and incubate at 37°C for 45 min; discard the secondary antibody, wash 6 times with PBST, add peroxidase substrate colorimetric solution at 100 μL / well, develop in the dark for 15-20 min, observe the color development effect, and add 50 μL / well 2M sulfuric acid to terminate the reaction after complete color development; use an enzyme reader at 492nm / 630nm dual wavelength to measure the optical density value, and the data results are analyzed by GraphPad Prism 8 software.
[0167] The results are as follows Figure 4 As shown, A16-hFc specifically binds to BoNT / A-Hc antigen, but does not bind to other antigens or has very weak binding activity.
[0168] Example 6. Evaluation of the neutralizing activity of anti-botulinum toxin nanobody-hFc fusion protein
[0169] The neutralizing activity of the antibody was determined by mixing the antibody with a lethal dose of botulinum toxin type A in vitro and then injecting it into KM (Kunming) mice. KM mice were 4 per group, weighing 18-20 g and purchased from Beijing Sibeifu Biotechnology Co., Ltd. The evaluation method is as follows:
[0170] 1. Sample preparation:
[0171] Diluent: KH2PO4 0.7g, Na2HPO4·12H2O 2.4g, NaCl 6.8g, gelatin 2g, add water to 1L, autoclave;
[0172] Botulinum toxin solution: dilute botulinum toxin type A (purchased from China Food and Drug Inspection Institute) to 100×LD 50 / mL;
[0173] A16-hFc solution: a solution obtained by dissolving the fusion protein A16-hFc prepared in Example 4 in a diluent.
[0174] Horse botulinum antitoxin standard solution (BAT-A) is a solution obtained by dissolving horse anti-botulinum toxin serum (purchased from China Food and Drug Inspection Institute) in diluent.
[0175] 2. The specific experimental grouping plan is as follows:
[0176] (1) BoNT / A solution 20×LD 50 Group: Each KM mouse was intraperitoneally injected with 200 μL of 100×LD 50 / mL of botulinum toxin solution, so that the toxin dose contained in each injection solution is 20×LD 50 / Only.
[0177] (2) BoNT / A 20×LD 50 +A16-hFc-10μg group: The above botulinum toxin solution was mixed with the A16-hFc solution, and the volume of each group was supplemented to 2.5mL with diluent. After mixing evenly, the solution was incubated at 37℃ for 30min to obtain BoNT / A+A16-hFc solution, which was intraperitoneally injected into KM mice, with 500μL injected per mouse, so that the dose of BoNT / A was 20×LD 50 / mouse, so that the dose of A16-hFc in each injection solution is 10 μg / mouse.
[0178] (3) BoNT / A 20×LD 50 +A16-hFc-5μg group: The difference between this group and BoNT / A+A16-hFc-10μg group is that the dose of A16-hFc is 5μg / mouse, and the rest of the operation is the same as BoNT / A 20×LD 50 +A16-hFc-10μg group.
[0179] (4) BoNT / A 20×LD 50 +A16-hFc-2.5μg group: The difference between this group and BoNT / A+A16-hFc-10μg group is that the dose of A16-hFc is 2.5μg / mouse. The rest of the operation is the same as BoNT / A 20×LD 50 +A16-hFc-10μg group.
[0180] (5)BoNT / A 20×LD 50 +A16-hFc-1.25μg group: The difference between this group and BoNT / A+A16-hFc-10μg group is that the dose of A16-hFc is 1.25μg / mouse. The rest of the operation is the same as BoNT / A20×LD 50+A16-hFc-10μg group.
[0181] (6)BoNT / A 20×LD 50 +A16-hFc-0.625μg group: The difference between this group and BoNT / A+A16-hFc-10μg group is that the dose of A16-hFc is 0.625μg / mouse. The rest of the operation is the same as BoNT / A20×LD 50 +A16-hFc-10μg group.
[0182] (7)BoNT / A 20×LD 50 +BAT-A-0.2IU group: The botulinum toxin solution was mixed with the standard solution of horse botulinum antitoxin, and the volume of each group was supplemented to 2.5mL with diluent. After mixing evenly, the mixture was incubated at 37℃ for 30min to obtain BoNT / A+BAT-A solution, which was intraperitoneally injected into KM mice, with 500μL injected per mouse, so that the dose of botulinum toxin was 20×LD 50 / mouse, and the dose of horse botulinum antitoxin BAT-A was 0.2IU / mouse.
[0183] Four mice were injected into each experimental group, and the health status and survival of the mice were monitored for 7 days.
[0184] The results are as follows Figure 5 As shown, 2.5 μg of A16-hFc can completely neutralize 20×LD 50 Lethal dose of BoNT / A.
[0185] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. A nanobody targeting botulinum toxin type A or an antigen-binding fragment containing the nanobody, characterized in that: The nanobody has three complementary determining clusters CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is shown in SEQ ID No.2, the amino acid sequence of the CDR2 is shown in SEQ ID No.3, and the amino acid sequence of the CDR3 is shown in SEQ ID No.
4.
2. The nanobody or antigen-binding fragment according to claim 1, characterized in that The Nanobody is the following A1) or A2): A1) a Nanobody with an amino acid sequence as shown in SEQ ID No. 1; A2) A nanobody obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No.
1.
3. A biomaterial associated with the Nanobody of claim 1 or 2, wherein the biomaterial is any of the following: B1) a nucleic acid molecule encoding the Nanobody or antigen-binding fragment of claim 1 or 2; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the nucleic acid molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) A recombinant microorganism containing the recombinant vector described in B4).
4. The biomaterial according to claim 3, characterized in that B1) The nucleic acid molecule is a nucleic acid molecule encoding the Nanobody according to claim 1 or 2, in which the CDR1 encoding gene is nucleotides 76-99 of SEQ ID No.9, the CDR2 encoding gene is such as nucleotides 151-174 of SEQ ID No.9, and the CDR3 encoding gene is such as nucleotides 289-336 of SEQ ID No.
9.
5. A method for preparing the Nanobody according to claim 1 or 2, comprising the following steps: The nucleic acid molecule encoding the nanobody according to claim 1 or 2 is introduced into a recipient cell to obtain a transgenic cell expressing the nanobody, and the transgenic cell is cultured to obtain the nanobody.
6. The biomaterial according to claim 3 or 4 or the preparation method according to claim 5, characterized in that: B1) The nucleic acid molecule is any of the following: C1) a DNA molecule whose nucleotide sequence is shown as SEQ ID No.9; C2) a DNA molecule that hybridizes under stringent conditions with the DNA molecule defined in C1) and encodes said Nanobody; C3) A DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85% or more homology with any of the DNA sequences defined in C1) to C2) and encodes the Nanobody.
7. Nanobody-hFc fusion protein, characterized in that The nanobody-hFc fusion protein is a fusion of the nanobody or antigen-binding fragment of claim 1 or 2 with another molecule, wherein the other molecule includes an Fc domain of an immunoglobulin, a fluorescent protein, or a VHH with different specificity.
8. The nanobody-hFc fusion protein according to claim 7, characterized in that The fusion protein is any of the following: N1) a fusion protein with an amino acid sequence as shown in SEQ ID No.11; N2) A protein obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No.
11.
9. An ELISA detection kit targeting botulinum toxin type A, characterized in that: The kit comprises the nanobody according to claim 1 or 2, the biological material according to any one of claims 3-5, or the fusion protein according to claim 7 or 8.
10. Any of the following applications: E1) Use of the Nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a product for detecting botulinum toxin type A; E2) Use of the biological material according to any one of claims 3 to 5 in the preparation of a product for detecting botulinum toxin type A; E3) Use of the preparation method according to claim 6 or 7 in the preparation of a product for detecting botulinum toxin type A; E4) Use of the kit according to claim 9 in the preparation of a product for detecting botulinum toxin type A; E5) Use of the Nanobody of claim 1 or 2 in the preparation of a product bound to botulinum toxin type A; E6) Use of the biomaterial according to any one of claims 3 to 5 in the preparation of a product combined with botulinum toxin type A; E7) Use of the preparation method according to claim 6 or 7 in the preparation of a product combined with botulinum toxin type A; E8) Use of the kit according to claim 9 in the preparation of a product combined with botulinum toxin type A; E9) Use of the nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a botulinum toxin type A detection reagent; E10) Use of the Nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a botulinum toxin type A diagnostic reagent; E11) Use of the Nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a medicament for preventing and / or treating botulinum toxin type A infection.
Citation Information
Patent Citations
Nanometer antibody for neutralizing botulinum toxin A
CN116925213A
Antibody HUXA148.49 for resisting botulinum toxin A and application of antibody HUXA148.49
CN117264051A
Nano antibody for resisting botulinum toxin and application of nano antibody
CN117736318A
Methods for detection of botulinum neurotoxin
US20130065259A1
Antibodies to botulinum neurotoxins
WO2023250381A2
Cited By
Antibody for long-acting neutralization of botulinum toxin A and application thereof
CN119462913A
Neutralizing antibody for resisting botulinum toxin L-HN antigen as well as related biological material and application thereof
CN119613539A
